All In Biotech

Drug Trial Radar · NCT05291689

A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

39

Actual

Start

Apr 13, 2022

Primary completion

Oct 18, 2023

Study completion Feb 19, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)

Conditions

  • Inflammatory Bowel Diseases
  • Colitis, Ulcerative

Interventions

  • MORF-057Drug

    MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) ScoreTime frame: From baseline to 12 weeks

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Study Site

    Tampa, Florida

  • Clinical Study Site

    Lafayette, Louisiana

  • Clinical Study Site

    Freehold, New Jersey

  • Clinical Study Site

    Brooklyn, New York

  • Clinical Study Site

    New York, New York

  • Clinical Study Site

    Bydgoszcz, Poland

  • Clinical Study Site

    Elblag, Poland

  • Clinical Study Site

    Katowice, Poland

  • Clinical Study Site

    Lodz, Poland

  • Clinical Study Site

    Lodz, Poland

  • Clinical Study Site

    Oświęcim, Poland

  • Clinical Study Site

    Sopot, Poland

  • Clinical Study Site

    Sosnowiec, Poland

  • Clinical Study Site

    Staszów, Poland

  • Clinical Study Site

    Tychy, Poland

  • Clinical Study Site

    Warsaw, Poland

  • Clinical Study Site

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.